[go: up one dir, main page]

MX2012014849A - Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada. - Google Patents

Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada.

Info

Publication number
MX2012014849A
MX2012014849A MX2012014849A MX2012014849A MX2012014849A MX 2012014849 A MX2012014849 A MX 2012014849A MX 2012014849 A MX2012014849 A MX 2012014849A MX 2012014849 A MX2012014849 A MX 2012014849A MX 2012014849 A MX2012014849 A MX 2012014849A
Authority
MX
Mexico
Prior art keywords
succinate
acetate
methyl cellulose
hydroxypropyl methyl
substitution
Prior art date
Application number
MX2012014849A
Other languages
English (en)
Inventor
Warren K Miller
David K Lyon
Dwayne T Friesen
William B Caldwell
David T Vodak
Daniel E Dobry
Original Assignee
Dow Global Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44627135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012014849(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Global Technologies Llc filed Critical Dow Global Technologies Llc
Publication of MX2012014849A publication Critical patent/MX2012014849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B13/00—Preparation of cellulose ether-esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/32—Cellulose ether-esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen polímeros de acetato succinato de hidroxipropil metil celulosa (HPMCAS) con grados únicos de substitución de grupos hidroxipropoxi, metoxi, acetilo y succinoilo. Cuando se usan para hacer composiciones comprendiendo un agente activo de baja solubilidad y tales polímeros, los polímeros proporcionan concentraciones acuosas incrementadas y/o estabilidad físiça mejorada del agente activo.
MX2012014849A 2010-06-14 2011-06-13 Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada. MX2012014849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35452510P 2010-06-14 2010-06-14
PCT/US2011/040222 WO2011159626A1 (en) 2010-06-14 2011-06-13 Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution

Publications (1)

Publication Number Publication Date
MX2012014849A true MX2012014849A (es) 2013-05-01

Family

ID=44627135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014849A MX2012014849A (es) 2010-06-14 2011-06-13 Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada.

Country Status (11)

Country Link
US (1) US9040033B2 (es)
EP (1) EP2579896B1 (es)
JP (1) JP5792807B2 (es)
KR (1) KR101807338B1 (es)
CN (1) CN103153343B (es)
BR (1) BR112012031667A2 (es)
CA (1) CA2801712A1 (es)
CO (1) CO6660473A2 (es)
IL (1) IL223607A (es)
MX (1) MX2012014849A (es)
WO (1) WO2011159626A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
MY182136A (en) 2010-11-24 2021-01-18 Melinta Subsidiary Corp Pharmaceutical compositions
WO2013106433A1 (en) * 2012-01-09 2013-07-18 Virginia Tech Intellectual Properties, Inc. Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs
WO2013148154A1 (en) * 2012-03-27 2013-10-03 Dow Global Technologies Llc A process of preparing an ester of a cellulose ether
EP2836205B1 (en) 2012-04-11 2016-10-19 Dow Global Technologies LLC Esterified cellulose ethers having a specific substituent distribution
CN102807625A (zh) * 2012-08-23 2012-12-05 浙江中维药业有限公司 一种醋酸羟丙甲纤维素琥珀酸酯的制备方法
JP6224711B2 (ja) 2012-08-24 2017-11-01 ダウ グローバル テクノロジーズ エルエルシー 部分架橋結合型エステル化セルロースエーテル
EP2888292B1 (en) * 2012-08-24 2019-04-10 Dow Global Technologies LLC Process for preparing an ester of a cellulose ether in the presence of an alkali metal carboxylate
BR112015002055A2 (pt) * 2012-08-24 2017-07-04 Dow Global Technologies Llc acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório
CN104755503B (zh) * 2012-08-24 2018-03-06 陶氏环球技术有限责任公司 在脂族羧酸的存在下制备纤维素醚的酯的方法
CN104797604B (zh) 2012-08-24 2018-03-06 陶氏环球技术有限责任公司 在碱金属羧酸盐和脂族羧酸的存在下制备酯化纤维素醚的方法
JP6456849B2 (ja) * 2013-03-01 2019-01-23 ハーキュリーズ・インコーポレーテッドＨｅｒｃｕｌｅｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 高められた性能及び改善された加工性を有する医薬組成物
EP2964203B1 (en) 2013-03-07 2019-04-03 Dow Global Technologies LLC Novel esterified cellulose ethers of very high molecular weight
KR102110120B1 (ko) * 2013-03-07 2020-05-14 다우 글로벌 테크놀로지스 엘엘씨 저점도의 신규한 에스테르화된 셀룰로스 에테르
CN105025887B (zh) * 2013-03-07 2017-07-28 陶氏环球技术有限责任公司 新颖极低粘度酯化纤维素醚
BR112015019354A2 (pt) * 2013-03-07 2017-07-18 Dow Global Technologies Llc acetato succinato de hidroxipropil metilcelulose, composição, dispersão sólida, forma de dosagem, envoltório de cápsula e processo para produzir um acetato succinato de hidroxipropil metilcelulose
WO2014186185A1 (en) 2013-05-14 2014-11-20 Dow Global Technologies Llc Cellulose ethers esterified with dicarboxylic acids
CN105283203B (zh) 2013-06-03 2018-12-28 信越化学工业株式会社 用于热熔挤出的组合物以及通过使用该组合物制备热熔挤出物的方法
KR101674912B1 (ko) * 2013-09-23 2016-11-10 다우 글로벌 테크놀로지스 엘엘씨 반응 생성물 혼합물로부터 에스테르화된 셀룰로스 에테르를 회수하기 위한 방법
KR102286952B1 (ko) * 2013-12-31 2021-08-09 롯데정밀화학 주식회사 입도분포가 조절된 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트(hpmcas) 입자의 제조방법 및 hpmcas 분말
US10759873B2 (en) 2014-02-20 2020-09-01 Dow Global Technologies Llc Esterified cellulose ethers of high molecular weight and homogeneity
CN106661130B (zh) 2014-08-27 2020-07-24 陶氏环球技术有限责任公司 不溶于丙酮的含量低的酯化纤维素醚
US20160113906A1 (en) 2014-09-19 2016-04-28 Board Of Regents, The University Of Texas System Methods of preparing extrudates
CN104311674A (zh) * 2014-10-17 2015-01-28 广东东阳光药业有限公司 一种混合酯的制备方法
KR101839294B1 (ko) * 2014-10-31 2018-04-27 다우 글로벌 테크놀로지스 엘엘씨 셀룰로오스 에테르 아세테이트 석시네이트의 생산 방법
EP3212674B1 (en) * 2014-10-31 2018-08-22 Dow Global Technologies LLC Process for preparing an ester of a cellulose ether
WO2016069343A1 (en) 2014-10-31 2016-05-06 Dow Global Technologies Llc Efficient process for preparing an ester of a cellulose ether
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
MX2017011128A (es) 2015-03-16 2017-11-28 Dow Global Technologies Llc Eteres de celulosa esterificada de gelificacion.
KR20170128358A (ko) 2015-03-16 2017-11-22 다우 글로벌 테크놀로지스 엘엘씨 낮은 중화도를 갖는 수용성 에스테르화 셀룰로오스 에테르
US20180071396A1 (en) * 2015-03-16 2018-03-15 Dow Global Technologies Llc Aqueous solution of an esterified cellulose ether
US10377835B2 (en) 2015-03-16 2019-08-13 Dow Global Technologies Llc Water-soluble esterified cellulose ethers
KR20170128349A (ko) * 2015-03-16 2017-11-22 다우 글로벌 테크놀로지스 엘엘씨 지방족 카복실산의 존재하에서의 에스테르화된 셀룰로오스 에테르의 제조 방법
EP3294776B1 (en) 2015-05-15 2020-08-05 Dow Global Technologies LLC Process of preparing a high molecular weight esterified cellulose ether
WO2016186897A1 (en) 2015-05-15 2016-11-24 Dow Global Technologies Llc Process for producing esterified cellulose ethers of very high molecular weight and low viscosity
KR20180036724A (ko) * 2015-07-28 2018-04-09 다우 글로벌 테크놀로지스 엘엘씨 에스테르화된 셀룰로오스 에테르의 분산물을 생성하는 방법
US11142633B2 (en) * 2015-10-02 2021-10-12 Nutrition & Biosciences Usa 1, Llc Aqueous composition comprising dispersed esterified cellulose ether
CN108348466A (zh) * 2015-12-08 2018-07-31 陶氏环球技术有限责任公司 包含纤维素醚和水溶性酯化纤维素醚的组合物
US9884922B2 (en) * 2016-03-11 2018-02-06 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate, method for producing the same and composition containing the same
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
JP2019531390A (ja) * 2016-10-18 2019-10-31 ダウ グローバル テクノロジーズ エルエルシー エステル化セルロースエーテルを調製する効率的な方法
KR102490265B1 (ko) * 2016-11-02 2023-01-20 신에쓰 가가꾸 고교 가부시끼가이샤 히프로멜로오스아세트산에스테르숙신산에스테르 및 제조 방법
US20210115161A1 (en) * 2017-03-17 2021-04-22 Dow Global Technologies Llc Process for Recovering an Esterified Cellulose Ether from a Reaction Product Mixture
EP3700574B1 (en) * 2017-10-27 2024-08-28 Plexxikon Inc. Formulations of a compound modulating kinases
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN115651085B (zh) * 2022-11-14 2023-11-17 乳源东阳光药业有限公司 一种醋酸羟丙甲纤维素琥珀酸酯的纯化方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226981A (en) 1977-09-28 1980-10-07 Shin-Etsu Chemical Co., Ltd. Ether-ester derivatives of cellulose and their applications
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
EP1745774A3 (en) * 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
WO2002038126A2 (en) 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
ATE409462T1 (de) 2004-05-28 2008-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
US20080213383A1 (en) * 2005-09-06 2008-09-04 Astellas Pharma Inc. Fine particles of poorly water-soluble drug having enteric material adsorbed on particle surface
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents

Also Published As

Publication number Publication date
US20130102691A1 (en) 2013-04-25
KR101807338B1 (ko) 2018-01-10
IL223607A (en) 2016-04-21
CN103153343A (zh) 2013-06-12
CA2801712A1 (en) 2011-12-22
CO6660473A2 (es) 2013-04-30
WO2011159626A1 (en) 2011-12-22
US9040033B2 (en) 2015-05-26
EP2579896B1 (en) 2016-07-20
BR112012031667A2 (pt) 2016-11-08
EP2579896A1 (en) 2013-04-17
JP2013532151A (ja) 2013-08-15
JP5792807B2 (ja) 2015-10-14
CN103153343B (zh) 2015-02-11
KR20130109102A (ko) 2013-10-07

Similar Documents

Publication Publication Date Title
MX2012014849A (es) Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada.
WO2005115330A3 (en) Pharmaceutical compositions with enhanced performance
MX2015010398A (es) Composiciones farmaceuticas con rendimiento mejorado y capacidad de procesamiento mejorada.
GEAP202112996A (en) Formulations of rifaximin and uses thereof
MX2016008448A (es) Conjugados de var2csa-farmaco.
EP2401264A4 (en) PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR USE
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
ECSP11011557A (es) Mimético de smac
MX344742B (es) Composicion de formacion de pelicula para capsulas suaves.
BR112013016212A2 (pt) composição aquosa de cuidado oral compreendendo goma xantana, goma de celulose e carbômero.
WO2011103150A3 (en) Lyophilized preparations of bendamustine
WO2010104310A3 (ko) 크랙 저항성을 갖는 시멘트 모르타르용 혼화제 및 이를 포함하는 시멘트 모르타르
PH12013501311A1 (en) Polymer systems
TR201010683A1 (tr) Vildagliptin formülasyonları.
WO2012131378A3 (en) Pharmaceutical preparation comprising alpha emitting radionuclide
CL2008003230A1 (es) Composicion de recubrimiento de tableta que comprende polimero celulosico, plastificante, edulcorante y composicion de sabor en polvo la que comprende saborizante asociado con portador solido; fluido de recubrimiento de tableta que comprende dicha composicion; tableta farmaceutica; proceso de preparacion de dicha tableta.
WO2013160349A3 (en) Cosmetic composition comprising a phosphorylated oligosaccharide and a polysaccharide
MX2011006567A (es) Formulaciones de fenilefrina con estabilidad mejorada.
BR112015015202B8 (pt) Composição
GEP201706769B (en) Composition of tiacumicin compounds
MX2010004072A (es) Composicion farmaceutica de orlistat.
FR2969611B1 (fr) Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
WO2012018742A3 (en) Dextromethorphan antitussive compositions
MX340232B (es) Uso prebiotico de polisacarido de soja soluble en agua.
BRPI0511583A (pt) composições farmacêuticas com desempenho aumentado

Legal Events

Date Code Title Description
FG Grant or registration